The prevalence of smoking among hospitalised COVID-19 patients is low. COVID-19 manifestations could be linked to impairment of the cholinergic anti-inflammatory pathway. Nicotinic cholinergic agonists should be examined as potential therapeutic options.https://bit.ly/2zfUZ1S
No takes yet. Share an insight, caveat, or question.
Farsalinos et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: